Nuclear medicine technology firm Positrigo of Zurich, Switzerland, has secured European market clearance for its dedicated brain PET system, NeuroLF.
NeuroLFImage courtesy of Positrigo
The imaging device is designed to help diagnose and monitor brain diseases such as Alzheimer's disease, brain tumors, epilepsy, Parkinson's disease, and others. The company received U.S. Food and Drug Administration clearance for NeuroLF in July.












![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





